Inhibition of mouse SP2/0 myeloma cell growth by the B7-H4 protein vaccine |
| |
| Authors: | Nan Mu Nannan Liu Qiang Hao Yujin Xu Jialin Li Weina Li Shouzhen Wu Cun Zhang Haichuan Su |
| |
| Institution: | 1.State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy;2.Experiment Teaching Center of Basic Medicine, The Fourth Military Medical University, 17 Changle West Road, 710032 Xi’an, Shaanxi, People’s Republic of China;3.Department of Oncology, Tangdu Hospital, Fourth Military Medical University, 1 Xinsi Road, 710038, Xi’an, Shaanxi, People’s Republic of China |
| |
| Abstract: | B7-H4 is a member of B7 family of co-inhibitory molecules and B7-H4 protein is found to be overexpressed in many human cancers and which is usually associated with poor survival. In this study, we developed a therapeutic vaccine made from a fusion protein composed of a tetanus toxoid (TT) T-helper cell epitope and human B7-H4IgV domain (TT-rhB7-H4IgV). We investigated the anti-tumor effect of the TT-rhB7-H4IgV vaccine in BALB/c mice and SP2/0 myeloma growth was significantly suppressed in mice. The TT-rhB7-H4IgV vaccine induced high-titer specific antibodies in mice. Further, the antibodies induced by TT-rhB7-H4IgV vaccine were capable of depleting SP2/0 cells through complement-dependent cytotoxicity (CDC) in vitro. On the other hand, the poor cellular immune response was irrelevant to the therapeutic efficacy. These results indicate that the recombinant TT-rhB7-H4IgV vaccine might be a useful candidate of immunotherapy for the treatment of some tumors associated with abnormal expression of B7-H4. BMB Reports 2014; 47(7): 399-404] |
| |
| Keywords: | B7-H4 Tumor Escape T-helper Epitope Tetanus Toxoid Tumor Vaccine |
|
|
